Life as a Flight Attendant During COVID-19: I Don’t Care

 

 

This week on I Don’t Care, Kevin Stevenson invited a very special guest on to the show to discuss the impact of the COVID-19 crisis on the airline industry. Kevin’s wife, Michelle, is a flight attendant for a major airline and gave some insight into the enhanced cleaning protocols, crew safety and changes in air travel in light of the current health crisis facing most of the world.

On another MarketScale podcast, Roads, Rails, & Rides, Jeb Morris brought up a staggering number in the reduction of travel in North America right now. TSA has reported as having gone from 2 million passengers a day going through security last March to roughly an average of 200,000 people going through security. With a 90% drop off in air travel many pilots, flight attendants, and passengers have reported being on a flight with fewer than 10 passenger onboard. Even with the steep drop off in business it is more cost effective to keep the planes in the air going to their next destination than it is to cancel some routes and bringing new planes to cover the active routes.

Michelle Stevenson discusses how her employer has increased the frequency of deep cleaning the aircraft from at the end of each day to even in between flights. Despite the drop in the usage of each seat, airlines are more focused than ever to make sure to disinfect all surfaces that would be susceptible to transmission of the virus.

Airlines across the industry are reconciling with the uncertain future of air travel by determining when furloughs are necessary and how to keep as many employees as possible active. To accommodate the reduction in active routes, some airlines are allowing crew members to have the option of extended time off to reduce the strain of active employees.

If you are interested in reading statements from airlines about how they are handling the COVID crisis we have linked the statements from the major airlines below.

American Airlines

Delta

Southwest

United

Catch upon previous episodes of I Don’t Care with Kevin Stevenson!

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More